LaFleur & Godfrey LLC Reduces Position in Zoetis Inc. (NYSE:ZTS)

LaFleur & Godfrey LLC cut its position in Zoetis Inc. (NYSE:ZTS - Free Report) by 25.6% during the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 26,654 shares of the company's stock after selling 9,158 shares during the period. LaFleur & Godfrey LLC's holdings in Zoetis were worth $4,389,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other large investors also recently modified their holdings of ZTS. Mission Wealth Management LP increased its stake in Zoetis by 2.0% during the fourth quarter. Mission Wealth Management LP now owns 2,938 shares of the company's stock valued at $479,000 after purchasing an additional 59 shares during the last quarter. HUB Investment Partners LLC increased its stake in Zoetis by 4.7% during the fourth quarter. HUB Investment Partners LLC now owns 1,373 shares of the company's stock valued at $224,000 after purchasing an additional 62 shares during the last quarter. Coppell Advisory Solutions LLC increased its stake in Zoetis by 18.0% during the fourth quarter. Coppell Advisory Solutions LLC now owns 420 shares of the company's stock valued at $68,000 after purchasing an additional 64 shares during the last quarter. Lindbrook Capital LLC increased its stake in Zoetis by 1.8% during the fourth quarter. Lindbrook Capital LLC now owns 3,650 shares of the company's stock valued at $595,000 after purchasing an additional 65 shares during the last quarter. Finally, Ironwood Investment Management LLC increased its stake in Zoetis by 0.8% during the fourth quarter. Ironwood Investment Management LLC now owns 8,354 shares of the company's stock valued at $1,361,000 after purchasing an additional 68 shares during the last quarter. 92.80% of the stock is owned by hedge funds and other institutional investors.

Zoetis Stock Performance

ZTS stock opened at $157.51 on Tuesday. The company has a market capitalization of $70.13 billion, a P/E ratio of 28.28, a PEG ratio of 2.61 and a beta of 0.94. The company has a 50-day simple moving average of $159.72 and a 200 day simple moving average of $163.10. Zoetis Inc. has a fifty-two week low of $139.70 and a fifty-two week high of $200.33. The company has a quick ratio of 1.04, a current ratio of 1.74 and a debt-to-equity ratio of 1.12.

Zoetis (NYSE:ZTS - Get Free Report) last posted its quarterly earnings data on Tuesday, May 6th. The company reported $1.48 earnings per share for the quarter, topping the consensus estimate of $1.40 by $0.08. The business had revenue of $2.22 billion during the quarter, compared to the consensus estimate of $2.20 billion. Zoetis had a net margin of 27.12% and a return on equity of 55.48%. The company's quarterly revenue was up 1.4% compared to the same quarter last year. During the same quarter in the prior year, the company posted $1.38 earnings per share. Sell-side analysts predict that Zoetis Inc. will post 6.07 earnings per share for the current fiscal year.

Zoetis Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, September 3rd. Investors of record on Friday, July 18th will be issued a $0.50 dividend. This represents a $2.00 annualized dividend and a yield of 1.27%. The ex-dividend date of this dividend is Friday, July 18th. Zoetis's payout ratio is currently 35.91%.

Insiders Place Their Bets

In other Zoetis news, EVP Roxanne Lagano sold 652 shares of the business's stock in a transaction dated Tuesday, June 3rd. The shares were sold at an average price of $170.00, for a total value of $110,840.00. Following the sale, the executive vice president now directly owns 15,129 shares in the company, valued at approximately $2,571,930. The trade was a 4.13% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 0.16% of the stock is owned by company insiders.

Wall Street Analyst Weigh In

Several research firms have weighed in on ZTS. Stifel Nicolaus lowered shares of Zoetis from a "buy" rating to a "hold" rating and lowered their target price for the company from $165.00 to $160.00 in a research note on Wednesday, June 18th. Wall Street Zen raised shares of Zoetis from a "hold" rating to a "buy" rating in a report on Friday, March 7th. Piper Sandler boosted their price target on shares of Zoetis from $205.00 to $210.00 and gave the company an "overweight" rating in a report on Monday, May 12th. Finally, UBS Group reduced their price target on shares of Zoetis from $189.00 to $170.00 and set a "neutral" rating for the company in a report on Wednesday, May 7th. Two analysts have rated the stock with a hold rating, seven have given a buy rating and two have assigned a strong buy rating to the company. According to data from MarketBeat, Zoetis currently has an average rating of "Buy" and a consensus price target of $212.13.

About Zoetis

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.